Genzyme Sues Over Endo's Bid To Sell Generic Renvela
Genzyme Corp. on Wednesday filed suit in Maryland accusing Endo Pharmaceuticals Inc. of infringing its patent covering Renvela by seeking approval to sell a generic version of the kidney disease treatment...To view the full article, register now.
Already a subscriber? Click here to view full article